Covishield

BIOLOGICAL2 trials

Sponsors

Institute of Liver and Biliary Sciences, India, Bharat Biotech International Limited

Conditions

COVID-19 Respiratory InfectionLiver Cirrhosis

Phase 3

Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose

CompletedNCT05567471

Bharat Biotech International LimitedCOVID-19 Respiratory Infection

Start: 2022-02-26End: 2022-09-28Updated: 2022-10-05

Unknown Phase

Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis

Institute of Liver and Biliary Sciences, IndiaLiver Cirrhosis

Start: 2021-03-19End: 2022-03-19Target: 2200Updated: 2021-06-23

Related Papers

Effect of heterologous intranasal iNCOVACC<sup>®</sup> vaccination as a booster to two-dose intramuscular Covid-19 vaccination series: a randomized phase 3 clinical trial.

2025-04-231 citations

Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin<sup>®</sup>).

2023-08-1856 citations